OBJECTIVES: To investigate the mechanisms of platelet kinetics in the Strategies for Management of Antiretroviral Therapy (SMART) study that demonstrated excess mortality with CD4 guided episodic antiretroviral therapy (ART) drug conservation compared with continuous treatment viral suppression. Follow-up analyses of stored plasma samples demonstrated increased activation of both inflammatory and coagulation pathways after stopping ART. DESIGN: SMART patients from sites that determined platelets routinely. METHODS: Platelet counts were retrospectively collected from 2206 patients from visits at study entry, and during follow-up. D-dimer levels were measured at study entry, month 1, and 2. RESULTS: Platelet levels decreased in the drug conservation group following randomization, but remained stable in the viral suppression group [median (IQR) decline from study entry to month 4: -24 000/μl (-54 000 to 4000) vs. 3000 (-22 000 to 24 000), respectively, P < 0.0001)] and the rate of developing thrombocytopenia (<100 000/μl) was significantly higher in the drug conservation vs. the viral suppression arm (unadjusted drug conservation/viral suppression [HR (95%CI) = 1.8 (1.2-2.7)]. The decline in platelet count among drug conservation participants on fully suppressive ART correlated with the rise in D-dimer from study entry to either month 1 or 2 (r = -0.41; P = 0.02). Among drug conservation participants who resumed ART 74% recovered to their study entry platelet levels. CONCLUSION: Interrupting ART increases the risk of thrombocytopenia, but reinitiation of ART typically reverses it. Factors contributing to declines in platelets after interrupting ART may include activation of coagulation pathways or HIV-1 replication itself. The contribution of platelets in HIV-related procoagulant activity requires further study.
OBJECTIVES: To investigate the mechanisms of platelet kinetics in the Strategies for Management of Antiretroviral Therapy (SMART) study that demonstrated excess mortality with CD4 guided episodic antiretroviral therapy (ART) drug conservation compared with continuous treatment viral suppression. Follow-up analyses of stored plasma samples demonstrated increased activation of both inflammatory and coagulation pathways after stopping ART. DESIGN: SMART patients from sites that determined platelets routinely. METHODS: Platelet counts were retrospectively collected from 2206 patients from visits at study entry, and during follow-up. D-dimer levels were measured at study entry, month 1, and 2. RESULTS: Platelet levels decreased in the drug conservation group following randomization, but remained stable in the viral suppression group [median (IQR) decline from study entry to month 4: -24 000/μl (-54 000 to 4000) vs. 3000 (-22 000 to 24 000), respectively, P < 0.0001)] and the rate of developing thrombocytopenia (<100 000/μl) was significantly higher in the drug conservation vs. the viral suppression arm (unadjusted drug conservation/viral suppression [HR (95%CI) = 1.8 (1.2-2.7)]. The decline in platelet count among drug conservation participants on fully suppressive ART correlated with the rise in D-dimer from study entry to either month 1 or 2 (r = -0.41; P = 0.02). Among drug conservation participants who resumed ART 74% recovered to their study entry platelet levels. CONCLUSION: Interrupting ART increases the risk of thrombocytopenia, but reinitiation of ART typically reverses it. Factors contributing to declines in platelets after interrupting ART may include activation of coagulation pathways or HIV-1 replication itself. The contribution of platelets in HIV-related procoagulant activity requires further study.
Authors: Andrea Costantini; Simona Giuliodoro; Stefania Mancini; Luca Butini; Christina M Regnery; Guido Silvestri; Francesco Greco; Pietro Leoni; Maria Montroni Journal: AIDS Date: 2006-08-22 Impact factor: 4.177
Authors: C Rivière; F Subra; K Cohen-Solal; V Cordette-Lagarde; R Letestu; C Auclair; W Vainchenker; F Louache Journal: Blood Date: 1999-03-01 Impact factor: 22.113
Authors: Nicholas T Funderburg; Elizabeth Mayne; Scott F Sieg; Robert Asaad; Wei Jiang; Magdalena Kalinowska; Angel A Luciano; Wendy Stevens; Benigno Rodriguez; Jason M Brenchley; Daniel C Douek; Michael M Lederman Journal: Blood Date: 2009-10-14 Impact factor: 22.113
Authors: Jason V Baker; Jacqueline Neuhaus; Daniel Duprez; Lewis H Kuller; Russell Tracy; Waldo H Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Daniel E Nixon; Nicholas I Paton; James D Neaton Journal: J Acquir Immune Defic Syndr Date: 2011-01-01 Impact factor: 3.731
Authors: Lars Peters; Amanda Mocroft; Vincent Soriano; Jürgen Rockstroh; Andri Rauch; Anders Karlsson; Brygida Knysz; Christian Pradier; Kai Zilmer; Jens D Lundgren Journal: PLoS One Date: 2013-05-27 Impact factor: 3.240
Authors: Jason V Baker; Kathleen Brummel-Ziedins; Jacqueline Neuhaus; Daniel Duprez; Nathan Cummins; David Dalmau; Jack DeHovitz; Clara Lehmann; Ann Sullivan; Ian Woolley; Lewis Kuller; James D Neaton; Russell P Tracy Journal: J Am Heart Assoc Date: 2013-07-29 Impact factor: 5.501
Authors: Moses M Obimbo; Yan Zhou; Michael T McMaster; Craig R Cohen; Zahida Qureshi; John Ong'ech; Julius A Ogeng'o; Susan J Fisher Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731